We are always being told by marketers of healthy yogurts that the human gut contains a bustling community of different bacteria, both good and bad, and that this balance is vital to keeping you healthy.
But if you target the disease-causing bacteria with medicine, what might be the collateral damage to their health-associated cousins that call the human body home?
A new study by Les Dethlefsen et al, to be published this week in the online open-access journal PLoS Biology, looks into the changes that happen in the human gut when it is exposed to the widely used antibiotic, ciprofloxacin. Ciprofloxacin is prescribed for a number of conditions, including common afflictions such as urinary tract infections. It was previously believed to cause only modest harm to the abundant beneficial bacteria of the human body.
To investigate ciprofloxacin's effect on health-associated bacteria a team of researchers, led by Dr. David Relman of Stanford University, catalogued types of bacteria present in the faeces of volunteers who were undergoing a course of treatment of ciprofloxacin. The DNA-analysis technique, massively-parallel pyrosequencing, was central to their approach, which is outlined in a companion paper scheduled for publication in PLoS Genetics on Friday the 21st of November. With this technique, the researchers examined the diversity and abundance of bacteria present in human faeces, identifying over 5,600 different bacterial species and strains. The dramatically increased detection power of this approach allowed the team to track carefully the changes in the gut's bacterial community both during and after the course of treatment.